1. 18 years of age or older

2. Hepatitis C virus (HCV) infection (denoted by positive HCV antibody and detectable HCV RNA)

3. Initiating oral HCV therapy with glecaprevir/pibrentasvir or sofosbuvir/velpatasvir

4. HCV treatment provided and managed by the clinical pharmacist at UI Health

5. Access to a mobile smartphone (iPhone 7 or later; Android release date 2012 or later) with reliable data and/or Wi-Fi access

6. Ability to verbalize understanding of the study protocol in English

7. Able and willing to provide informed consent in English

HCV Tappt Adherence Study